Description

Bupropion Tablets

Healthy Inc is a specialized global supplier and exporter of advanced CNS, psychiatry, and targeted neurological therapeutics. We provide ultra-high-purity, kinetically optimized Bupropion HCl Tablets, manufactured in WHO–GMP certified, high-precision specialized CNS facilities. Available in Sustained-Release (SR) and Extended-Release (XL) formats, this “NDRI & Smoking Cessation Aid” is a massive-volume export to mental health clinics, addiction centers, and government health ministries, serving as the globally mandated intervention for Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and Nicotine Dependence.

Product Overview

This formulation operates as a stimulating metabolic and neurological regulator. By focusing on dopamine and norepinephrine—the “Reward and Focus” chemicals—Bupropion provides an energizing therapeutic effect that differs significantly from traditional sedating antidepressants.

• Mechanism 1 (NDRI Pathway): Bupropion inhibits the neuronal reuptake of Dopamine and Norepinephrine. By increasing the concentration of these neurotransmitters in the synaptic cleft, it restores emotional balance, improves concentration, and enhances motivation.

• Mechanism 2 (Smoking Cessation – Nicotinic Antagonism): Bupropion acts as a non-competitive antagonist at Nicotinic Acetylcholine Receptors. It mimics the dopamine “reward” of a cigarette, physically reducing the intensity of nicotine cravings and withdrawal symptoms.

• Mechanism 3 (The “Weight-Neutral” Advantage): Because it does not affect Serotonin or Histamine receptors, Bupropion is uniquely associated with weight neutrality or modest weight loss, making it the “Gold Standard” for patients concerned about metabolic side effects.

Technical & Logistics Specifications

• HS Code: 3004.90.72 (Medicaments containing antidepressants)

• CAS Number: 34911-55-2 (Bupropion) / 31677-93-7 (Bupropion HCl)

• Dosage Form: Controlled-Release Film-Coated Tablet

• Packaging: Alu-Alu Blisters or HDPE Bottles. Bupropion is sensitive to moisture; our moisture-lock packaging ensures 24-month stability in Zone IVb tropical climates.

Manufacturing Authority & Compliance

• Release Profile Accuracy: Our facility utilizes Advanced Laser-Drilled or Polymeric Coating Technology to ensure the SR and XL release curves exactly match the innovator brand (Wellbutrin/Zyban), preventing “dose dumping.”

• Solvent-Free Aqueous Coating: We utilize eco-friendly aqueous coating systems to ensure a high-purity finish without residual solvent odors, which is critical for patient compliance in long-term CNS therapy.

Dosage & Administration

• MDD (XL): Usually started at 150 mg once daily in the morning; can be increased to 300 mg.

• Smoking Cessation (SR): Treatment should begin while the patient is still smoking; a “Quit Date” is set within the first 2 weeks of treatment.

• The “No-Crush” Rule (CRITICAL): SR and XL tablets MUST be swallowed whole. Crushing or chewing the tablet destroys the time-release matrix, leading to rapid absorption and a significant increase in the risk of seizures.

Safety Warning: Seizure Risk. Strictly contraindicated in patients with a history of seizure disorders, anorexia, or bulimia. Avoid abrupt withdrawal of alcohol or sedatives while on Bupropion. Monitor for increased blood pressure and neuropsychiatric changes.

Global Export & Contract Manufacturing

Healthy Inc is a premier Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for high-precision Controlled-Release CNS drugs. Whether you are a Mental Health Hospital Buyer in Africa or a B2B Pharma Marketplace partner in the CIS, we ensure secure, WHO-GMP compliant delivery.